Imugene Ltd

AU:IMU Australia Biotechnology
Market Cap
$36.20 Million
AU$58.46 Million AUD
Market Cap Rank
#23729 Global
#475 in Australia
Share Price
AU$0.18
Change (1 day)
+0.00%
52-Week Range
AU$0.01 - AU$0.48
All Time High
AU$0.61
Categories
Companies in Australia Biotechnology
About

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more

Imugene Ltd (IMU) - Net Assets

Latest net assets as of December 2025: AU$41.87 Million AUD

Based on the latest financial reports, Imugene Ltd (IMU) has net assets worth AU$41.87 Million AUD as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$67.67 Million) and total liabilities (AU$25.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$41.87 Million
% of Total Assets 61.87%
Annual Growth Rate 7.04%
5-Year Change -30.74%
10-Year Change 473.18%
Growth Volatility 161.02

Imugene Ltd - Net Assets Trend (1993–2025)

This chart illustrates how Imugene Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Imugene Ltd (1993–2025)

The table below shows the annual net assets of Imugene Ltd from 1993 to 2025.

Year Net Assets Change
2025-06-30 AU$45.03 Million -61.92%
2024-06-30 AU$118.25 Million -37.64%
2023-06-30 AU$189.63 Million +36.71%
2022-06-30 AU$138.70 Million +113.33%
2021-06-30 AU$65.02 Million +8.71%
2020-06-30 AU$59.81 Million +119.11%
2019-06-30 AU$27.29 Million +76.37%
2018-06-30 AU$15.48 Million +35.81%
2017-06-30 AU$11.39 Million +45.03%
2016-06-30 AU$7.86 Million +1.61%
2015-06-30 AU$7.73 Million +14.85%
2014-06-30 AU$6.73 Million +256.87%
2013-06-30 AU$1.89 Million +75.74%
2012-06-30 AU$1.07 Million -74.48%
2011-06-30 AU$4.21 Million +10.96%
2010-06-30 AU$3.79 Million -28.82%
2009-06-30 AU$5.33 Million +14.05%
2008-06-30 AU$4.67 Million -0.63%
2007-06-30 AU$4.70 Million -27.27%
2006-06-30 AU$6.46 Million -25.31%
2005-06-30 AU$8.65 Million +59.30%
2004-06-30 AU$5.43 Million -27.03%
2003-06-30 AU$7.44 Million +838.83%
2002-06-30 AU$792.83K +449.97%
2001-06-30 AU$-226.54K -108.15%
2000-06-30 AU$2.78 Million -53.65%
1999-06-30 AU$6.00 Million -11.25%
1998-06-30 AU$6.75 Million -9.35%
1997-06-30 AU$7.45 Million -8.25%
1996-06-30 AU$8.12 Million -23.53%
1995-06-30 AU$10.62 Million -5.05%
1994-06-30 AU$11.19 Million +118.86%
1993-06-30 AU$5.11 Million --

Equity Component Analysis

This analysis shows how different components contribute to Imugene Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 35029661900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$380.68 Million 845.35%
Other Comprehensive Income AU$17.08 Million 37.92%
Total Equity AU$45.03 Million 100.00%

Imugene Ltd Competitors by Market Cap

The table below lists competitors of Imugene Ltd ranked by their market capitalization.

Company Market Cap
Simula Technology
TWO:3511
 		$29.30 Million
Novem Group S.A.
F:NVM
 		$29.31 Million
Altair Minerals Ltd
AU:ALR
 		$29.31 Million
AVTECH Sweden AB Series B
ST:AVT-B
 		$29.31 Million
Casino Guichard Perrachon SA
PA:CO
 		$29.30 Million
Rabbit Holdings PCL
BK:RABBIT
 		$29.29 Million
Al-Salam Real Estate Investment Trust
KLSE:5269
 		$29.29 Million
PTL LTD Ordinary Shares
NASDAQ:PTLE
 		$29.29 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Imugene Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 118,254,407 to 45,032,333, a change of -73,222,074 (-61.9%).
  • Net loss of 69,021,612 reduced equity.
  • Share repurchases of 1,320,000 reduced equity.
  • New share issuances of 1,579 increased equity.
  • Other comprehensive income decreased equity by 20,695,326.
  • Other factors increased equity by 17,813,285.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-69.02 Million -153.27%
Share Repurchases AU$1.32 Million -2.93%
Share Issuances AU$1.58K +0.0%
Other Comprehensive Income AU$-20.70 Million -45.96%
Other Changes AU$17.81 Million +39.56%
Total Change AU$- -61.92%

Book Value vs Market Value Analysis

This analysis compares Imugene Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.87x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.01x to 0.87x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1993-06-30 AU$17.50 AU$0.18 x
1994-06-30 AU$10.63 AU$0.18 x
1995-06-30 AU$7.61 AU$0.18 x
1996-06-30 AU$5.59 AU$0.18 x
1997-06-30 AU$4.54 AU$0.18 x
1998-06-30 AU$3.85 AU$0.18 x
1999-06-30 AU$2.76 AU$0.18 x
2000-06-30 AU$1.16 AU$0.18 x
2001-06-30 AU$-0.09 AU$0.18 x
2002-06-30 AU$0.06 AU$0.18 x
2003-06-30 AU$0.10 AU$0.18 x
2004-06-30 AU$0.05 AU$0.18 x
2005-06-30 AU$2.43 AU$0.18 x
2006-06-30 AU$1.67 AU$0.18 x
2007-06-30 AU$1.21 AU$0.18 x
2008-06-30 AU$1.15 AU$0.18 x
2009-06-30 AU$1.19 AU$0.18 x
2010-06-30 AU$0.89 AU$0.18 x
2011-06-30 AU$0.99 AU$0.18 x
2012-06-30 AU$0.25 AU$0.18 x
2013-06-30 AU$0.20 AU$0.18 x
2014-06-30 AU$0.33 AU$0.18 x
2015-06-30 AU$0.22 AU$0.18 x
2016-06-30 AU$0.20 AU$0.18 x
2017-06-30 AU$0.19 AU$0.18 x
2018-06-30 AU$0.20 AU$0.18 x
2019-06-30 AU$0.01 AU$0.18 x
2020-06-30 AU$0.50 AU$0.18 x
2021-06-30 AU$0.47 AU$0.18 x
2022-06-30 AU$0.84 AU$0.18 x
2023-06-30 AU$0.03 AU$0.18 x
2024-06-30 AU$0.57 AU$0.18 x
2025-06-30 AU$0.21 AU$0.18 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Imugene Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -153.27%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -1569.81%
  • • Asset Turnover: 0.05x
  • • Equity Multiplier: 1.86x
  • Recent ROE (-153.27%) is below the historical average (-49.26%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1993 4.75% 0.00% 0.00x 1.11x AU$-268.10K
1994 -7.82% 0.00% 0.00x 1.01x AU$-1.99 Million
1995 -20.10% -1135.64% 0.02x 1.12x AU$-3.20 Million
1996 -52.25% -1526.62% 0.03x 1.14x AU$-5.06 Million
1997 -29.28% -56.54% 0.44x 1.17x AU$-2.93 Million
1998 -67.30% 0.00% 0.00x 1.17x AU$-5.22 Million
1999 -82.24% -511.27% 0.14x 1.15x AU$-5.53 Million
2000 -159.02% -1303.54% 0.09x 1.32x AU$-4.70 Million
2001 0.00% -3537.32% 0.05x 0.00x AU$-4.02 Million
2002 -98.63% -60.53% 1.53x 1.07x AU$-861.28K
2003 9.39% 3679263.16% 0.00x 1.09x AU$-45.27K
2004 -38.96% -1706.45% 0.02x 1.11x AU$-2.66 Million
2005 -20.73% -460.00% 0.04x 1.05x AU$-2.66 Million
2006 -33.84% -831.56% 0.04x 1.12x AU$-2.83 Million
2007 -49.02% -146564.89% 0.00x 1.12x AU$-2.77 Million
2008 -40.92% -2077.17% 0.02x 1.11x AU$-2.38 Million
2009 12.21% 21.50% 0.52x 1.08x AU$117.65K
2010 -40.49% -3488.64% 0.01x 1.08x AU$-1.91 Million
2011 9.88% 18.66% 0.48x 1.11x AU$-5.15K
2012 -291.87% -1328.04% 0.18x 1.23x AU$-3.24 Million
2013 -82.69% -752.82% 0.08x 1.37x AU$-1.75 Million
2014 -31.43% -393.08% 0.06x 1.28x AU$-2.79 Million
2015 -31.57% -382.20% 0.07x 1.18x AU$-3.21 Million
2016 -34.76% -174.62% 0.16x 1.21x AU$-3.52 Million
2017 -22.00% -215.38% 0.09x 1.11x AU$-3.65 Million
2018 -25.42% -213.69% 0.11x 1.09x AU$-5.48 Million
2019 -28.49% -188.39% 0.13x 1.13x AU$-10.50 Million
2020 -17.57% -254.18% 0.06x 1.09x AU$-16.49 Million
2021 -28.38% -255.19% 0.10x 1.10x AU$-24.96 Million
2022 -27.30% -291.97% 0.09x 1.06x AU$-51.74 Million
2023 -19.99% -321.91% 0.06x 1.04x AU$-56.88 Million
2024 -126.58% -3011.67% 0.03x 1.28x AU$-161.51 Million
2025 -153.27% -1569.81% 0.05x 1.86x AU$-73.52 Million

Industry Comparison

This section compares Imugene Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $31,815,679
  • Average return on equity (ROE) among peers: -60.84%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Imugene Ltd (IMU) AU$41.87 Million 4.75% 0.62x $29.30 Million
Adalta Ltd (1AD) $2.03 Million -265.03% 1.74x $171.91K
Algorae Pharmaceuticals Ltd (1AI) $2.88 Million -33.65% 0.18x $9.99 Million
ACRUX Ltd (ACR) $17.49 Million -17.99% 0.05x $2.16 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $11.42 Million
Arovella Therapeutics Ltd (ALA) $11.23 Million -77.89% 0.18x $39.76 Million
Anatara Lifesciences Ltd (ANR) $5.92 Million -48.49% 0.08x $718.75K
Bio-Gene Technology Ltd (BGT) $4.25 Million -56.43% 0.18x $2.33 Million
BTC Health Ltd (BTC) $11.34 Million -4.81% 0.03x $364.22
Cambium Bio Ltd (CMB) $8.27 Million -79.86% 0.16x $8.11 Million
Clinuvel Pharmaceuticals Ltd (CUV) $240.81 Million 15.02% 0.13x $251.65 Million